ClinicalTrials.gg
CompletedNCT01398956Updated Aug 15, 2017Results posted

An Open Label Study of L059 (Levetiracetam) in Japanese Epilepsy Subjects With Generalized Tonic-clonic Seizures

A Phase 3 interventional study of Levetiracetam in Epilepsy and Generalized Tonic-clonic Seizures, sponsored by UCB Pharma. Completed at 32 sites in Japan. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
36th of 60
44 · median 94
Started
2011
with 4 others
Phase 3
28 of 60
2 open now
Registered
42nd of 60
by date
Lead sponsor
23 of 60
UCB Pharma

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 36th largest by enrollment, is one of 5 that started in 2011, is one of 28 in phase 3, and was the 42nd registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

The investigators will provide Levetiracetam treatment to epilepsy subjects in Japan who are judged to benefit from continued treatment with Levetiracetam by the investigators and who are willing to continuously receive this drug.

03

Conditions studied

  • Epilepsy
  • Generalized Tonic-clonic Seizures

Keywords

  • Levetiracetam
  • Epilepsy
  • Generalized tonic-clonic seizures
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject in Japan has completed either of the studies N01159 or N01363 or has discontinued the N01159 study due to lack of efficacy.
  • The subject who is judged to benefit from continued treatment with Levetiracetam by the investigators

Exclusion criteria

Exclusion Criteria:

  • Subjects with multiple protocol deviations during N01159 or N01363, such as missing laboratory data, and low or noncompliance with the study medication, and who the investigator considers not to have the potential to have deviations stopped are ineligible
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Twice daily (morning and evening) orally

    Drug: Levetiracetam

Interventions

  • formulation: tablet or dry syrup strength: 250 mg tablet, 500 mg tablet, dry syrup 50% dosage: Sb ≥16 years and ≥4 and \<16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and \<16 years (\<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day frequency: twice daily

    Also known as: Keppra, E Keppra

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment Emergent Adverse Events During the Entire Study Period

    Time frame: Through study completion, an average of 3 years

Secondary outcomes

  1. The Percentage Change in Generalized Tonic-Clonic (GTC) Seizure Frequency Per Week Over the Evaluation Period From Either of the Combined Baseline Periods of the Previous Studies (N01159 or N01363).

    Percentage change in generalized tonic-clonic (GTC) seizure frequency per week from Baseline of previous studies B over the Treatment Period A is calculated using the equation: Percentage change from Baseline = ((A-B)/B)\*100. Percentage change from baseline is not defined for subjects whose baseline information is missing / unknown or equal to zero, or whose seizure frequency per week is missing/unknown. A negative value in change in generalized tonic-clonic (GTC) seizure frequency indicates a reduction of generalized tonic-clonic (GTC) seizure frequency over the Treatment Period.

    Time frame: During the Treatment Period (up to 4.8 years)

  2. The Incidence of Adverse Drug Reactions During the Entire Study Period

    Adverse drug reactions excludes Adverse Events (AEs) described by the investigators with no relationship to study drug.

    Time frame: Through study completion, an average of 3 years

07

Results

Posted Mar 9, 2017

Participant flow

This study started to enroll subjects in Japan in June 2011.

Participant flow — Overall Study
MilestoneLevetiracetam
Started44
Completed34
Not completed10
Withdrew: Withdrawal by subject4
Withdrew: Ae, non-serious non-fatal4
Withdrew: Withdrawal criteria no.31
Withdrew: Subject moved a long distance1

Outcome measures

PrimaryIncidence of Treatment Emergent Adverse Events During the Entire Study Period
Time frame:
Through study completion, an average of 3 years
Reported as:
Number · Treatment Emergent Adverse Events
Incidence of Treatment Emergent Adverse Events During the Entire Study Period
Treatment Emergent Adverse EventsLevetiracetam (SS)
Incidence of Treatment Emergent Adverse Events During the Entire Study Period626
SecondaryThe Percentage Change in Generalized Tonic-Clonic (GTC) Seizure Frequency Per Week Over the Evaluation Period From Either of the Combined Baseline Periods of the Previous Studies (N01159 or N01363).

Percentage change in generalized tonic-clonic (GTC) seizure frequency per week from Baseline of previous studies B over the Treatment Period A is calculated using the equation: Percentage change from Baseline = ((A-B)/B)\*100. Percentage change from baseline is not defined for subjects whose baseline information is missing / unknown or equal to zero, or whose seizure frequency per week is missing/unknown. A negative value in change in generalized tonic-clonic (GTC) seizure frequency indicates a reduction of generalized tonic-clonic (GTC) seizure frequency over the Treatment Period.

Time frame:
During the Treatment Period (up to 4.8 years)
Reported as:
Median · percent change
The Percentage Change in Generalized Tonic-Clonic (GTC) Seizure Frequency Per Week Over the Evaluation Period From Either of the Combined Baseline Periods of the Previous Studies (N01159 or N01363).
percent changeLevetiracetam (FAS)
The Percentage Change in Generalized Tonic-Clonic (GTC) Seizure Frequency Per Week Over the Evaluation Period From Either of the Combined Baseline Periods of the Previous Studies (N01159 or N01363).-92.07 (-97.16 to -64.64)
SecondaryThe Incidence of Adverse Drug Reactions During the Entire Study Period

Adverse drug reactions excludes Adverse Events (AEs) described by the investigators with no relationship to study drug.

Time frame:
Through study completion, an average of 3 years
Reported as:
Number · Adverse Drug Reactions
The Incidence of Adverse Drug Reactions During the Entire Study Period
Adverse Drug ReactionsLevetiracetam (SS)
The Incidence of Adverse Drug Reactions During the Entire Study Period46

Adverse events

Collected over Adverse Events (AEs) were collected from Visit 1 (Week 0) until Safety Follow Up Visit (up to 4.7 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam (SS)—13/44 (29.5%)41/44 (93.2%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventLevetiracetam (SS)
InfluenzaInfections and infestations2/44
Acute tonsillitisInfections and infestations1/44
BronchitisInfections and infestations1/44
BronchopneumoniaInfections and infestations1/44
PharyngotonsillitisInfections and infestations1/44
Pneumonia respiratory syncytial viralInfections and infestations1/44
Postoperative wound infectionInfections and infestations1/44
Cervical vertebral fractureInjury, poisoning and procedural complications1/44
Femoral neck fractureInjury, poisoning and procedural complications1/44
Medical observationInvestigations1/44
Most frequent other events
Showing 10 of 29
Most frequent other events
EventLevetiracetam (SS)
NasopharyngitisInfections and infestations35/44
ConvulsionNervous system disorders16/44
Dental cariesGastrointestinal disorders11/44
SomnolenceNervous system disorders10/44
InfluenzaInfections and infestations9/44
HeadacheNervous system disorders9/44
DiarrhoeaGastrointestinal disorders8/44
PyrexiaGeneral disorders8/44
ConstipationGastrointestinal disorders7/44
ContusionInjury, poisoning and procedural complications7/44

Baseline characteristics

The Baseline Characteristics refer to the Safety Set (SS) which consisted of all subjects who took at least one dose of study medication in this study.

Age, Categorical
Age, Categorical(Participants)Levetiracetam
<=18 years15
Between 18 and 65 Years28
>=65 years1
Age, Continuous
Age, Continuous(years)Levetiracetam
Mean26.1 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam
Female16
Male28
08

Study locations

32 sites
  • 152
    Fujisawa, Japan
  • 112
    Fukuoka, Japan
  • 113
    Fukuoka, Japan
  • 165
    Fukuoka, Japan
  • 166
    Fukuoka, Japan
  • 187
    Fukushima, Japan
  • 107
    Gifu, Japan
  • 162
    Himeji, Japan
  • 110
    Hiroshima, Japan
  • 117
    Hokkaido, Japan
  • 130
    Hokkaido, Japan
  • 176
    Hokkaido, Japan
  • 143
    Kagoshima, Japan
  • 156
    Kagoshima, Japan
  • 120
    Kodaira, Japan
  • 105
    Kokubunji, Japan
  • 306
    Koshi, Japan
  • 172
    Miyazaki, Japan
  • 179
    Miyazaki, Japan
  • 305
    Nagoya, Japan
  • 106
    Niigata, Japan
  • 153
    Niigata, Japan
  • 109
    Okayama, Japan
  • 174
    Osaka, Japan
  • 119
    Saitama, Japan
  • 147
    Sakai, Japan
  • 194
    Sakai, Japan
  • 304
    Sapporo, Japan
  • 138
    Tochigi, Japan
  • 184
    Tokyo, Japan
  • 190
    Tokyo, Japan
  • 111
    Ube, Japan
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Apr 2016 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2017, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2011
First posted
Jul 21, 2011
Start
Jun 2011
Primary completionActual
Apr 2016
CompletionActual
Apr 2016
Results first posted
Mar 9, 2017
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01398956
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Jul 21, 2011
Start date
Jun 2011
Primary completion
Apr 2016
Completion
Apr 2016
Results posted
Mar 9, 2017
Last update
Aug 15, 2017

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion